Hubei Biocause Heilen Pharmaceutical Co., Ltd. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was CNY 193.29 million compared to CNY 128.25 million a year ago. Revenue was CNY 193.29 million compared to CNY 128.25 million a year ago.

Net income was CNY 39.92 million compared to CNY 27.96 million a year ago. Basic earnings per share from continuing operations was CNY 0.1417 compared to CNY 0.1 a year ago. Diluted earnings per share from continuing operations was CNY 0.1417 compared to CNY 0.1 a year ago.